Maribavir
- PMID: 37360201
- PMCID: PMC10288452
- DOI: 10.1177/00185787221101480
Maribavir
Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
Keywords: anti-infectives; drug information; formulary management/P & T.
© The Author(s) 2022.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
-
- Livtencity (maribavir) [prescribing information]. Takeda Pharmaceuticals America Inc; 2021.
-
- Cidofovir [Prescribing Information]. Mylan Institutional LLC; 2021.
-
- Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. Food and Drug Administration. Updated January 2022. Accessed January 19, 2022. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
-
- Foscavir (foscarnet sodium) [prescribing information]. Hospira Inc; 2020.
Publication types
LinkOut - more resources
Full Text Sources